Federal Tylenol Litigation Looks Ahead to Status Conference in July, to Discuss Lawsuits Alleging Liver Damage
New York, NY (PRWEB) July 05, 2014 -- An upcoming conference involving Tylenol lawsuits (http://www.tylenollawsuitcenter.com/) has been scheduled to take place later this month in the U.S. District Court, Eastern District of Pennsylvania, where a federal multidistrict litigation is continuing to move forward, Bernstein Liebhard LLP reports.
According to a calendar posted on the Court’s website, parties involved in the federal proceeding will convene on July 17th, 2014 at 10:00 a.m. to discuss issues related to cases over the Johnson & Johnson pain reliever. Court documents indicate that dozens of Tylenol-related claims allege similar injuries caused by its active ingredient, acetaminophen. Plaintiffs in these cases allegedly experienced liver damage that occurred after label directions were properly followed and may have necessitated hospitalization, the need for a transplant, and/or death. (In Re: Tylenol (Acetaminophen) Marketing, Sales Practices and Products Liability Litigation, MDL No. 2436)
“Our Firm is looking forward to further progress in the federal litigation involving Tylenol lawsuits, as our attorneys continue to hear from individuals who allegedly suffered liver damage side effects of Tylenol,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of dangerous drugs and medical devices in the U.S. The Firm is currently offering free and confidential case evaluations to individuals who may have been harmed as a result of over-the-counter Tylenol products.
Tylenol Lawsuits
Court records indicate that Tylenol lawsuits filed in the Eastern District of Pennsylvania are continuing to move forward, with at least 140 claims alleging acetaminophen-related injuries now pending in the multidistrict litigation. Some of these cases may have been filed after the U.S. Food and Drug Administration (FDA) announced in April that prescription medications containing more than 325 milligrams of acetaminophen were being voluntarily taken off the market after regulators considered them to be no longer safe.*
This FDA alert was issued almost a year after Bloomberg.com reported that the amount of acetaminophen included in over-the-counter Extra Strength Tylenol caplets exceeded the FDA’s limits for prescription drugs. That same month, McNeil Consumer Healthcare announced it would adjust warning labels on Tylenol products to include more prominent warnings about liver damage.**
Individuals who allegedly suffered Tylenol liver damage may be eligible to receive compensation for injury-related damages. Learn more about the possible association between Tylenol and liver damage when you visit Bernstein Liebhard LLP’s website. You may also arrange for a free legal review by calling 800-511-5092.
*http://www.latimes.com/science/sciencenow/la-sci-sn-extra-strength-acetaminophen-fda-20140428,0,6108401.story, LA Times, April 28, 2014
**http://www.bloomberg.com/news/2013-08-29/j-j-adds-warning-to-tylenol-caps-on-acetaminophen-risk.html, Bloomberg.com, August 29, 2013
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York States contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firms fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.tylenollawsuitcenter.com/
https://plus.google.com/115936073311125306742?rel=author
Felecia L. Stern, Tylenol Lawsuit Information Center, http://www.tylenollawsuitcenter.com/, +1 800-511-5092, [email protected]
Share this article